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Abstract
Background: Regular HIV testing among people who inject drugs is an essential component of HIV prevention
and treatment efforts. We explored HIV testing behaviour among a community-recruited sample of injection drug
users (IDU) in Bangkok, Thailand.
Methods: Data collected through the Mitsampan Community Research Project were used to examine correlates of
HIV testing behaviour among IDU and to explore reasons for not being tested. Multivariate logistic regression was
used to examine factors associated with willingness to access HIV testing at the drug-user-run Mitsampan Harm
Reduction Centre (MSHRC).
Results: Among the 244 IDU who participated in this study, 186 (76.2%) reported receiving HIV testing in the
previous six months. Enrolment in voluntary drug treatment (odds ratio [OR] = 2.34; 95% confidence interval [CI]:
1.18 - 4.63) and the tenofovir trial (OR = 44.81; 95%CI: 13.44 - 149.45) were positively associated with having been
tested, whereas MSHRC use (OR = 1.78; 95%CI: 0.96 - 3.29) was marginally associated with having been tested.
56.9% of those who had not been tested reported in engaging in HIV risk behaviour in the past six months. 181
(74.2%) participants were willing to be tested at the MSHRC if testing were offered there. In multivariate analyses,
willingness to get HIV testing at the MSHRC was positively associated with ever having been to the MSHRC
(adjusted odds ratio [AOR] = 2.42; 95%CI: 1.21 - 4.85) and, among females, being enrolled in voluntary drug
treatment services (AOR = 9.38; 95%CI: 1.14 - 76.98).
Conclusions: More than three-quarters of IDU received HIV testing in the previous six months. However, HIV risk
behaviour was common among those who had not been tested. Additionally, 74.2% of participants were willing to
receive HIV testing at the MSHRC. These findings provide evidence for ongoing HIV prevention education, as well
potential benefits of incorporating HIV testing for IDU within peer-led harm reduction programs.
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Background
The HIV/AIDS epidemic remains a global challenge,
with an estimated 33.3 million people living with HIV
globally [1]. In many settings, the fastest growing epi-
demics of HIV are occurring among people who inject
drugs [2-4]. Currently, major public health efforts are
underway to scale-up HIV testing [5], as HIV testing
leads to early diagnosis, and knowledge of HIV-serosta-
tus may minimize HIV transmission by reducing risky
behaviour [6]. Further, testing can help increase access
to treatment for injection drug users (IDU) and thereby
reduce HIV-related morbidity and mortality, while also
bolstering prevention efforts by reducing HIV-I RNA to
undetectable levels in infected individuals [7].
Although there is much evidence to support efforts to
increase the accessibility of HIV testing among IDU,
there are many factors that mitigate the likelihood that
IDU will get tested. Barriers such as the fear of an HIV-
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positive test result, HIV-related stigma, and the resulting
impacts on relationships with family and public authori-
ties are among the reasons why IDU do not get tested
for HIV [8,9]. In Thailand, where the prevalence of HIV
among IDU is as high as 50% [10], an excessive focus
on drug law enforcement has likely contributed to the
suboptimal coverage of HIV prevention, treatment and
care among this population [11,12]. For example, some
public hospitals reportedly collect and share information
concerning patients’ drug use behaviour with police in
Thailand [11]. This compromising of patient confidenti-
ality prevents many IDU from wanting to use govern-
ment testing services, especially given that, in order to
qualify for a free HIV test at public testing clinics, IDU
must declare their risk behaviour (P. Sririrund, personal
communication, April 30, 2011). In addition, if IDU
were to get HIV testing at private clinics, there would
be the burden of the cost of an HIV test imposed upon
them. Collectively, these barriers could potentially
undermine access to HIV testing among this population.
Recent studies have found that uptake of HIV testing
among IDU in parts of Asia is as low as 20% annually
[13].
Several studies have shown that peer-based interven-
tions for drug users can often extend the reach and
effectiveness of conventional public health programs
[14,15], especially in settings where drug use is heavily
penalized, as in Thailand [16]. There has been increas-
ing interest in novel, low-threshold methods of HIV
testing, including peer-based testing [17,18]. However,
there are currently no peer-based models of HIV testing
in Thailand, and concerns have been expressed regard-
ing the inadequate voluntary counselling and HIV test-
ing services offered to IDU in this setting [11]. Given
that knowledge of HIV-positive serostatus can reduce
the health burden associated with HIV/AIDS among
IDU, and HIV testing and counselling continue to be
supported by international health organizations globally
[19,20], the lack of these services in Thailand has
prompted calls for increased voluntary counselling, test-
ing and information services across the country [11].
According to the Reference Group to the United
Nations on HIV and Injecting Drug Use, there are an
estimated 160,000 IDU living in Thailand [2], of whom
the majority are male and between the ages of 30-40
years [16,21]. While there exists some evidence indicat-
ing why individuals engaging in illicit drug use have low
uptake of HIV testing services [21], little is known about
the factors that influence HIV testing among IDU in
Thailand. Therefore, we sought to investigate the preva-
lence and correlates of HIV testing behaviour among a
community-recruited sample of IDU in Bangkok, Thai-
land. As well, given the growing interest in low-thresh-
old and peer-based HIV testing programs, we also
sought to assess willingness to get tested for HIV at a
drug-user-run drop-in centre in Bangkok.
Methods
The Mitsampan Community Research Project (MSCRP)
is a collaborative research project involving the Mitsam-
pan Harm Reduction Centre (Bangkok, Thailand), the
Thai AIDS Treatment Action Group (Bangkok, Thai-
land), Chulalongkorn University (Bangkok, Thailand)
and the British Columbia Centre for Excellence in HIV/
AIDS (Vancouver, Canada). During June and July of
2009, the research partners undertook a cross-sectional
study involving 317 community-recruited IDU. Potential
participants were recruited through peer-based outreach
efforts and word of mouth. Study participants were then
invited to attend the MSHRC to participate in the study.
All participants provided informed consent and com-
pleted an interviewer-administered questionnaire elicit-
ing information about demographic characteristics, drug
use, HIV risk behaviour, criminal justice system expo-
sure, and experiences with health care. All participants
were given 350 baht (approximately US$11) upon com-
pletion of the questionnaire. The study has been
approved by the research ethics boards of the University
of British Columbia and Chulalongkorn University.
For the present analyses, we restricted the study sam-
ple to individuals who were HIV-negative or of
unknown HIV serostatus. As a first step, we compared
IDU who had and had not been tested for HIV in the
past six months using the Pearson c2 test and Fisher’s
exact test (when one or more cells contained values less
than or equal to five). Among the participants who had
not been tested for HIV in the past six months, we
examined the prevalence of ongoing HIV risk behaviour
and asked them to indicate reasons why they had not
been tested. Second, we compared IDU who were and
were not willing to get free HIV testing at MSHRC,
again using the Pearson c2 test and Fisher’s exact test
(when one or more cells contained values less than or
equal to five). The “willingness to get free HIV testing
at MSHRC” variable referred to whether participants
would get tested at least once at the peer-run drop-in
centre. Specifically, we asked: “If the MSHRC offered
free HIV testing with pre- and post-counselling (includ-
ing referrals to clinics/hospitals), would you take the
test?” We then built a multivariate logistic regression
model to identify independent predictors of willingness
to get free HIV testing at MSHRC by including all vari-
ables that were associated with the outcome at the p ≤
0.10 level in bivariate analyses.
Variables considered in both initial bivariate analyses
included: gender, median age, relationship status (mar-
ried/common law, regular partner vs. separated, dating,
single), education level (≥ secondary school vs.
Ti et al. BMC Public Health 2012, 12:189
http://www.biomedcentral.com/1471-2458/12/189
Page 2 of 9
< secondary school), heroin injection in the past six
months (> once per week vs. ≤ once per week), midazo-
lam injection in the past six months (> once per week
vs. ≤ once per week), methamphetamine injection in the
past six months (> once per week vs. ≤ once per week),
lent or borrowed syringes to/from others in the past six
months (yes vs. no), enrolled in voluntary drug treat-
ment in the past six months (yes vs. no), had unpro-
tected sex in the past six months (yes vs. no),
incarceration in the past six months (yes vs. no), report-
ing barriers to accessing health services (any barriers vs.
no barriers), and having ever been to MSHRC (yes vs.
no). Our barriers to testing variable included the follow-
ing: limited hours of operation, long wait times, didn’t
know where to go, jail, detention, prison, no identifica-
tion, identification registered somewhere else, no
money, was treated poorly by healthcare professionals,
fear of sharing information of drug using status with the
police and/or narcotics control board, difficulty keeping
appointments, transportation, and others. Additionally,
because Bangkok was a site of the tenofovir trial (a pre-
exposure prophylaxis trial) that included IDU, being
enrolled in the tenofovir trial (yes vs. no) was also con-
sidered in the first bivariate analyses focused on HIV
testing behaviour in the past six months. All p-values
were two-sided.
Results
In total, 244 individuals who were HIV-negative or of
unknown HIV serostatus were included in the study,
including 77 (31.6%) females. The median age of the
participants at the time of interview was 37 years (range:
20 - 72 years). In total, 186 (76.2%) participants reported
that they had been tested for HIV in the past six
months. As indicated in Table 1, results show that being
enrolled in voluntary drug treatment in the past six
months (odds ratio [OR] = 2.34; 95% confidence interval
[CI]: 1.18 - 4.63) and being in the tenofovir trial (OR =
44.81; 95% CI: 13.44 - 149.45) were positively associated
with having been tested for HIV. As well, having been
to MSHRC (OR = 1.78; 95%CI: 0.96 - 3.29) was margin-
ally associated with having been tested for HIV.
Although the odds ratio for the incarceration variable
could not be calculated because one cell contained a
zero, there was a trend towards a positive association
between having been incarcerated in the past six months
and having been tested for HIV. Of the 58 participants
who were not tested for HIV, 41 responded to the ques-
tion: “Why haven’t you taken an HIV test?” Of these, 27
(65.9%) stated that they believed they were HIV-nega-
tive. However, 33 (56.9%) participants who did not get
an HIV test engaged in at least one of the following
risky behaviours in the past six months: syringe
borrowing, syringe lending, or unprotected vaginal or
anal intercourse.
In total, 181 (74.2%) participants responded that they
were willing to get tested at the MSHRC. As shown in
Table 2, factors positively associated with a willingness
to be tested for HIV at the MSHRC included being
enrolled in voluntary drug treatment in the past six
months (OR = 1.94; 95%CI: 1.02 - 3.68), reporting a bar-
rier to accessing health services (OR = 1.99; 95%CI: 1.05
- 3.77), and having been to the MSHRC (OR = 3.17;
95%CI: 1.68 - 6.01). There was also a marginally signifi-
cant association between willingness to get tested at the
MSHRC and having lent or borrowed syringes to/from
others in the past six months (OR = 2.36; 95%CI: 0.94 -
5.90). Additionally, female sex was negatively associated
with willingness to be tested for HIV at the MSHRC
(OR = 0.46; 95%CI: 0.26 - 0.84).
Table 3 presents the results of multivariate analyses of
factors associated with willingness to get HIV testing at
the MSHRC. As indicated here, having been to the
MSHRC (adjusted odds ratio [AOR] = 2.42; 95%CI: 1.21
- 4.85) remained positively associated with willingness to
get HIV testing at the peer-run drop-in centre. An ana-
lysis of interactions was then conducted between gender
and enrolment in voluntary drug treatment in the past
six months. A positive association between willingness
to be tested at the MSHRC and being enrolled in volun-
tary drug treatment was found for females (AOR = 9.38;
95%CI: 1.14 - 76.98), while a marginal positive associa-
tion between willingness to get tested for HIV at the
MSHRC and non-enrolment in voluntary drug treat-
ment was found for males (AOR = 2.07; 95%CI: 0.98 -
4.39).
Discussion
In the present study, we found that HIV testing was
common among Thai IDU, with 76.2% reporting that
they had been tested in the past six months. Having
been enrolled in voluntary drug treatment and being
enrolled in the tenofovir trial was positively associated
with having been tested for HIV, while having been to
the MSHRC was marginally associated. Among those
who had not been tested for HIV in the past six
months, approximately 56% had recently engaged in
some form of HIV risk behaviour. We also found that
almost three-quarters of the sample (74.2%) expressed
willingness to get tested for HIV at the drug-user-run
MSHRC. In a multivariate analysis, having been to
MSHRC was independently and positively associated
with willingness to get tested at MSHRC. Enrolment in
voluntary drug treatment was also associated with will-
ingness to get tested at the MSHRC, although this rela-
tionship interacted with gender, with women in
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Table 1 Bivariate analyses of factors associated with being tested for HIV in the past six months among IDU in
Bangkok, Thailand (n = 244)





Odds Ratio(95% CI) p - value
Gender
Female 54 (29.0) 23 (39.7) 0.62 (0.34 - 1.15) 0.13
Male 132 (71.0) 35 (60.3)
Median age
≥ 37 years old 96 (51.6) 24 (41.4) 1.51 (0.83 - 2.74) 0.17
< 37 years old 90 (48.4) 34 (58.6)
Relationship status
Married/common law, regular partner 100 (53.8) 33 (56.9) 0.88 (0.49 - 1.60) 0.68
Separated, dating, single 86 (46.2) 25 (43.1)
Education level
≥ secondary education 66 (35.5) 23 (39.7) 0.84 (0.46 - 1.53) 0.56
< secondary education 120 (64.5) 35 (60.3)
Heroin injection*
> once per week 54 (29.0) 17 (29.3) 0.99 (0.52 - 1.89) 0.97
≤ once per week 132 (71.0) 41 (70.7)
Midazolam injection*
> once per week 114 (61.3) 32 (55.2) 1.29 (0.71 - 2.33) 0.41
≤ once per week 72 (38.7) 26 (44.8)
Methamphetamine injection*
> once per week 71 (38.2) 18 (31.0) 1.37 (0.73 - 2.58) 0.32
≤ once per week 115 (61.8) 40 (69.0)
Lent or borrowed syringes to/from others*
Yes 33 (17.7) 9 (15.5) 1.17 (0.53 - 2.62) 0.70
No 153 (82.3) 49 (84.5)
Enrolled in voluntary drug treatment*
Yes 75 (40.3) 13 (22.4) 2.34 (1.18 - 4.63) 0.01
No 111 (59.7) 45 (77.6)
Had unprotected sex*
Yes 87 (46.8) 29 (50.0) 0.88 (0.49 - 1.59) 0.67
No 99 (53.2) 29 (50.0)
Incarceration*
Yes 11 (5.9) 0 (0.0) – 0.07
No 175 (94.1) 58 (100.0)
Reporting barriers to accessing health services
Any barriers 68 (36.6) 21 (36.2) 1.02 (0.55 - 1.87) 0.96
No barriers 118 (63.4) 37 (63.8)
Ever been to MSHRC
Yes 90 (48.4) 20 (34.5) 1.78 (0.96 - 3.29) 0.06
No 96 (51.6) 38 (65.5)
In tenofovir trial
Yes 132 (71.0) 3 (5.2) 44.81 (13.44 - 149.45) < 0.01
No 54 (29.0) 55 (94.8)
* Activities in the previous six months
IDU Injecting drug users
MSHRC Mitsampan Harm Reduction Centre
CI Confidence Interval
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Table 2 Bivariate analyses of factors associated with willingness to get free HIV testing at the MSHRC among IDU in
Bangkok, Thailand (n = 244)






Odds Ratio(95% CI) p - value
Gender
Female 49 (27.1) 28 (44.4) 0.46 (0.26 - 0.84) 0.01
Male 132 (72.9) 35 (55.6)
Median age
≥ 37 years old 92 (50.8) 28 (44.4) 1.29 (0.73 - 2.30) 0.38




103 (56.9) 30 (47.6) 1.45 (0.82 - 2.58) 0.20
Separated, dating, single 78 (43.1) 33 (52.4)
Education level
≥ secondary education 68 (37.6) 21 (33.3) 1.20 (0.66 - 2.20) 0.55
< secondary education 113 (62.4) 42 (66.7)
Heroin injection*
> once per week 56 (30.9) 15 (23.8) 1.43 (0.74 - 2.77) 0.28
≤ once per week 125 (69.1) 48 (76.2)
Midazolam injection*
> once per week 113 (62.4) 33 (52.4) 1.51 (0.85 - 2.69) 0.16
≤ once per week 68 (37.6) 30 (47.6)
Methamphetamine injection*
> once per week 70 (38.7) 19 (30.2) 1.46 (0.79 - 2.70) 0.23
≤ once per week 111 (61.3) 44 (69.8)
Lent or borrowed syringes to/from others*
Yes 36 (19.9) 6 (9.5) 2.36 (0.94 - 5.90) 0.06
No 145 (80.1) 57 (90.5)
Enrolled in voluntary drug treatment*
Yes 72 (39.8) 16 (25.4) 1.94 (1.02 - 3.68) 0.04
No 109 (60.22) 47 (74.6)
Had unprotected sex*
Yes 86 (47.5) 30 (47.6) 1.00 (0.56 - 1.77) 0.99
No 95 (52.5) 33 (52.4)
Incarceration*
Yes 10 (5.5) 1 (1.6) 3.63 (0.45 - 28.91) 0.30
No 171 (94.5) 62 (98.4)
Reporting barriers to accessing health services
Any barriers 73 (40.3) 16 (25.4) 1.99 (1.05 - 3.77) 0.03
No barriers 108 (59.7) 47 (74.6)
Ever been to MSHRC
Yes 94 (51.9) 16 (25.8) 3.17 (1.68 - 6.01) < 0.01
No 87 (48.1) 47 (74.6)
* Activities in the previous six months
IDU Injecting drug users
MSHRC Mitsampan Harm Reduction Centre
CI Confidence Interval
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treatment being the more willing to get tested at the
MSHRC.
We found that just over three-quarters (76.2%) of our
sample of IDU had previously been tested for HIV in
the past six months. Our findings are consistent with
previous studies demonstrating fairly high levels of HIV
testing in other middle-income settings contending with
high rates of HIV infection among IDU, including
Andhra Pradesh, India (89%) [22] and St. Petersburg,
Russia (76%) [23]. However, our findings are inconsis-
tent with previous studies that show low uptake of HIV
testing among IDU in Asia [13]. That said, it is unclear
whether the high rate of testing observed here is par-
tially a reflection of the existence of the tenofovir trial,
as 55% of participants had enrolled in this study.
Although HIV testing appears to be quite common
among IDU in Bangkok, there were still a number of
active drug-using participants who had not been tested
in the past six months. Among the participants who
were not tested for HIV, the majority perceived them-
selves to be HIV-negative even though they had engaged
in at least one HIV risk behaviour in the past six
months. This raises concern that some IDU in Thailand
may be unaware of their HIV risk, indicating a need for
intensified and targeted outreach, education and testing
efforts to reach these individuals [9,24]. Interestingly,
our findings reveal that the type of illicit drugs injected
(heroin, midazolam, and methamphetamine) was not
associated with either of our outcome variables, suggest-
ing that our findings are uniform across individuals who
use different types of drugs.
UNODC recommends community-based, voluntary
drug treatment programs across South East Asia as a
substitute for incarceration and compulsory drug deten-
tion centres for IDU [25]. Voluntary drug treatment
programs, in particular opiate substitution therapy
(OST), have been previously associated with a reduction
in risky behaviour and HIV infection among IDU in var-
ious settings [26-28]. Adding to the benefits of voluntary
treatment, we found that participants who were enrolled
in voluntary treatment were significantly more likely to
get tested for HIV compared to those who were not
enrolled in voluntary treatment. Our findings support
the recommendation of the United States Centres for
Disease Control and Prevention (US CDC) to integrate
HIV testing services as part of voluntary drug treatment
[29]. However, concerns have been raised about the nat-
ure of current HIV testing in voluntary drug treatment
centres in Thailand, as it has been reported that in
some of these centres, HIV testing is mandatory and a
condition of receiving services [11]. Given that our
study did not differentiate between mandatory and
voluntary HIV testing in voluntary treatment programs,
future research should seek to untangle this complex
relationship. Nevertheless, in these settings, replacing
the system of mandatory testing with voluntary HIV
testing in these treatment programs may prove to be
effective in increasing the proportion of IDU in Thai-
land who get tested, thereby allowing for early diagnosis,
enhanced access to antiretroviral therapy (ART) treat-
ment, and targeted education and interventions to con-
trol the spread of HIV [6].
Table 3 Multivariate logistic regression analyses of factors associated with willingness to get free HIV testing at
MSHRC among IDU in Bangkok, Thailand (n = 244)
Variable Adjusted Odds Ratio (AOR) 95% Confidence Interval (CI) p - value
Lent or borrowed syringes to/from others*
(yes vs. no) 1.49 (0.56 - 4.00) 0.43
Reporting barriers to accessing health services
(yes vs. no) 1.22 (0.59 - 2.51) 0.58
Ever been to MSHRC
(yes vs. no) 2.42 (1.21 - 4.85) 0.01
Gender (not enrolled in voluntary treatment*)
(male vs. female) 2.07 (0.98 - 4.39) 0.06
Gender (enrolled in voluntary treatment*)
(male vs. female) 0.22 (0.03 - 1.85) 0.16
Enrolled in voluntary drug treatment* (male)
(yes vs. no) 1.01 (0.46 - 2.18) 0.99
Enrolled in voluntary drug treatment* (female)
(yes vs. no) 9.38 (1.14 - 76.98) 0.04
*Activities in the previous six months
IDU Injection Drug Users
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In addition to being enrolled in voluntary drug treat-
ment, being enrolled in the tenofovir trial was also posi-
tively associated with HIV testing among IDU. The
tenofovir trial in Thailand, sponsored by the US CDC,
was launched in 2005 in an attempt to examine the
safety and efficacy of this antiretroviral drug. Currently,
tenofovir (alone) is being provided to approximately
2,400 HIV-negative IDU and 17 drug treatment clinics
across Bangkok [30]. Results of the US CDC-sponsored
pre-exposure prophylaxis trial in Thailand are to be
revealed in early 2012 [31]. The increased odds of HIV
testing among IDU in the tenofovir trial could be attrib-
uted to the fact that all participants in the trial receive
free rapid HIV testing on an ongoing basis. Although
our findings show a positive association between being
enrolled in the tenofovir trial and HIV testing, concerns
have been expressed over the fact that the trial sites in
Thailand failed to provide sterile syringes and needles to
IDU participants [32,33]. Efforts to engage and consult
with IDU community groups at an earlier stage of the
trial design process may have helped alleviate these con-
cerns and should be considered for future HIV preven-
tion trials as a means of ensuring appropriate access to
HIV prevention technologies among trial participants.
Internationally, peer outreach and peer-run initiatives
have been shown to be successful in extending the
reach and effectiveness of conventional public health
programs, including those focused on preventing and
treating HIV/AIDS among IDU [14,34,35]. Since the
launch of Thailand’s 2003 “War on Drugs” campaign,
the government has continued to rely on repressive
approaches to drugs, including arbitrary arrests, black-
listing, drug planting by police, extrajudicial executions
and other human rights violations of people involved
with drugs [11,36,37]. In this context, severe stigma and
discrimination persist against Thai IDU, prompting
many to avoid public health programs [37]. Additionally,
problems related to stigmatizing attitudes of health care
providers focused on IDU have been reported among
Thai health professionals, including nursing students,
which in turn likely adversely affects the willingness of
IDU to access health care [38]. Given these problems,
the noted effectiveness of various peer-based methods
for IDU, and the high willingness to access HIV testing
at the MSHRC, peer-based HIV testing interventions for
IDU may have high potential for success in this setting.
In the present study, having been to the MSHRC pre-
viously was significantly and positively associated with
willingness to get HIV testing at the centre. In an earlier
study conducted on the MSHRC, results showed that
the main reason IDU did not access the centre was the
lack of knowledge of its existence [16]. Therefore, future
efforts should focus on increasing awareness of and
improving access to the MSHRC and other drop-in cen-
tres like it. Since the focus of this paper was on willing-
ness to get HIV testing at the MSHRC without
specifying whether the testing was peer-delivered, future
research efforts should seek to determine whether IDU
would be willing to be tested by a peer either in the
context of a drug-user-run harm reduction program or
in other conventional health care settings.
Enrolment in voluntary drug treatment was also asso-
ciated with willingness to get HIV testing at the
MSHRC. As mentioned above, there was an interaction
effect involving enrolment in voluntary treatment and
gender, and willingness to get tested at the MSHRC.
Among participants who were not enrolled in voluntary
treatment, males were significantly more willing than
females to get tested at the MSHRC, although this asso-
ciation did not reach conventional significance. Among
female IDU, those engaged in treatment were signifi-
cantly more willing to get tested at the MSHRC com-
pared to those out of treatment. In light of these
findings, future research should seek to unpack the gen-
der dynamics surrounding addiction treatment enrol-
ment and HIV testing behaviour within this setting.
This study has several limitations. First, because of the
cross-sectional nature of the study, there is an inability
to determine a temporal relationship between exposure
and outcome, and therefore causation cannot be
inferred. Second, the data collected were self-reported
and may be subject to reporting biases. Socially desirable
reporting as well as recall bias may affect reports of both
risk behaviour and testing behaviour. Third, since the
study sample was small and not randomly selected, the
study may not be representative of Thai IDU. As well,
our findings may not be generalizable to other popula-
tions of IDU. Lastly, because of the small sample size,
there were wide intervals around some of the estimates
reported.
Conclusions
In the present study, we found high rates of HIV testing
among Thai IDU. However, we found that among parti-
cipants who were not tested for HIV, a high proportion
had recently engaged in some form of HIV risk beha-
viour. We also observed a high rate of willingness to get
free HIV testing at the MSHRC. Willingness to be
tested was independently associated with having been to
MSHRC, and among women, having been enrolled in
voluntary drug treatment was also associated with will-
ingness to be tested at the MSHRC. These findings
highlight the need for ongoing educational efforts
related to HIV transmission, as well opportunities to
expand harm reduction strategies to include peer-led
HIV testing for IDU in Thailand.
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